Jeffrey Coleman, Ph.D. is a partner in the Firm’s Intellectual Property group. Dr. Coleman is a seasoned intellectual property litigator who represents clients in complex, high-stakes disputes and counsels clients seeking to protect or enforce their IP rights.
His litigation practice spans every facet of patent litigation, from pre-suit analysis and investigation, fact and expert discovery, depositions, technical reports, claim construction, dispositive motions, trial and appeals. He has litigated disputes in federal courts in the United States and has coordinated multi-jurisdictional disputes across the globe with parallel ex-U.S. litigations.
Dr. Coleman has experience with both biotech/life sciences and high tech inventions and has represented clients in both fields. Within the biotech/life sciences field, he has represented clients in disputes involving small molecule pharmaceuticals and therapeutics, biologics, vaccines and injectables, medical devices, DNA/RNA technology, and molecular diagnostics. Within the high tech field, he has represented clients in disputes involving cell phone security technology, computer security technology, distributed mobile networks, and satellite radio and streaming music technologies. In addition to litigating in federal courts, Dr. Coleman has experience representing clients in inter partes review proceedings before the USPTO, and in proceedings before the U.S. International Trade Commission.
In addition to his litigation practice, he routinely advises clients on corporate and transactional matters involving intellectual property. For example, he has advised clients on development and commercialization of patents and patent portfolios, freedom to operate, patent licensing, due diligence, risk assessment, and subsidiary wind-down procedures where company intellectual property assets are involved.
Dr. Coleman currently serves as a member of the Board of Directors of the New York Intellectual Property Law Association. Prior to joining the Firm, he served as an officer and Treasurer of the NYIPLA, and as Co-Chair of the NYIPLA’s Amicus Briefs Committee. He is also a member of the American Bar Association.
In 2025, he was named to the Best Lawyers, “Ones to Watch” list in the field of Intellectual Property law.
Prior to joining Ellenoff Grossman & Schole LLP, he practiced law at several large law firms in New York. He received his J.D. cum laude from Fordham Law School, where he was the Executive Notes Editor of the Fordham Law Review. He also earned a Ph.D. in Molecular Toxicology from Penn State University, where his doctoral research focused on the prevention of pancreatic cancer metastasis using small molecule therapeutics. He also holds a B.S. degree in Chemistry from Ursinus College.